Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA1 | P30542 | 1/20 | 0.61 |
| ▸ | ADORA2B | P29275 | 10/20 | 0.52 |
| ▸ | RXFP1 | Q9HBX9 | 3/20 | 0.52 |
| ▸ | MAPT | P10636 | 1/20 | 0.49 |
| ▸ | LMNA | P02545 | 1/20 | 0.49 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19499799 | 0.96 | ADORA1 (0.62) | ADORA1ADORA2BRXFP1MAPTLMNA | |
| SCHEMBL19499803 | 0.89 | ADORA2B (0.60) | ADORA1ADORA2BRXFP1MAPTLMNA | |
| SCHEMBL17486884 | 0.89 | ADORA2B (0.58) | ADORA1ADORA2BRXFP1MAPTLMNA | |
| SCHEMBL19499801 | 0.89 | ADORA2B (0.60) | ADORA1ADORA2BRXFP1MAPTLMNA | |
| SCHEMBL17486881 | 0.89 | ADORA2B (0.60) | ADORA1ADORA2BRXFP1MAPTLMNA | |
| SCHEMBL17486888 | 0.83 | ADORA2B (0.51) | ADORA2BRXFP1MAPTLMNAALDH1A1 | |
| SCHEMBL19677779 | 0.83 | ADORA2B (0.49) | ADORA2BRXFP1MAPTLMNAALDH1A1 | |
| SCHEMBL17744966 | 0.83 | ADORA1 (0.75) | ADORA1ADORA2BRXFP1MAPTLMNA | |
| SCHEMBL19499800 | 0.82 | LMNA (0.63) | ADORA2BRXFP1MAPTLMNAALDH1A1 | |
| SCHEMBL19542267 | 0.80 | ADORA1 (0.55) | ADORA1ADORA2BRXFP1MAPTLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170312285-A1 | COMPOUNDS FOR THE TREATMENT OF MYOTONIC DYSTROPHY | SELABTEC SCIENCES, SL (ES) | 2017-11-02 | — | — | US | disclosed |
| US-20170304309-A1 | CAFFEINE FOR THE TREATMENT OF MYOTONIC DYSTROPHY TYPE 1 AND TYPE 2 | INSTITUT UNIV. DE CIENCIA I TECNOLOGIA, S.A. (ES) | 2017-10-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170304309-A1 | CAFFEINE FOR THE TREATMENT OF MYOTONIC DYSTROPHY TYPE 1 AND TYPE 2 | SMN1; SMN2, TDP2, MTPN | ADORA1 210/4885ADORA2B 972/4885RXFP1 1677/4885 |
| US-20170312285-A1 | COMPOUNDS FOR THE TREATMENT OF MYOTONIC DYSTROPHY | SMN1; SMN2, CPT1B, MTPN | ADORA1 790/4885ADORA2B 1199/4885RXFP1 2764/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.